Your browser is no longer supported. Please, upgrade your browser.
Entera Bio Ltd.
Index- P/E- EPS (ttm)-0.86 Insider Own31.53% Shs Outstand23.38M Perf Week-1.77%
Market Cap127.31M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float20.79M Perf Month-5.12%
Income-18.50M PEG- EPS next Q-0.12 Inst Own20.60% Short Float1.80% Perf Quarter-18.65%
Sales0.50M P/S254.63 EPS this Y39.00% Inst Trans13.87% Short Ratio2.22 Perf Half Y48.83%
Book/sh1.08 P/B4.12 EPS next Y31.00% ROA-111.40% Target Price- Perf Year312.04%
Cash/sh0.94 P/C4.73 EPS next 5Y- ROE-163.40% 52W Range1.01 - 10.16 Perf YTD312.04%
Dividend- P/FCF- EPS past 5Y-8.50% ROI-157.10% 52W High-56.20% Beta1.64
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin52.10% 52W Low340.59% ATR0.21
Employees19 Current Ratio8.30 Sales Q/Q0.00% Oper. Margin- RSI (14)42.55 Volatility3.25% 4.94%
OptionableYes Debt/Eq0.02 EPS Q/Q-26.00% Profit Margin- Rel Volume0.32 Prev Close4.32
ShortableYes LT Debt/Eq0.01 EarningsAug 16 BMO Payout- Avg Volume167.82K Price4.45
Recom2.00 SMA20-4.91% SMA50-7.61% SMA20017.19% Volume53,682 Change3.01%
Mar-22-21Initiated Aegis Capital Buy $12
Oct-06-21 03:47PM  
Sep-17-21 08:09AM  
Sep-01-21 08:30AM  
Aug-23-21 11:00AM  
Aug-19-21 09:04AM  
Aug-16-21 06:30AM  
Aug-13-21 04:30PM  
Aug-06-21 10:20AM  
Aug-02-21 08:30AM  
Jun-28-21 03:15PM  
Jun-25-21 06:23PM  
Jun-24-21 12:38PM  
Jun-23-21 08:30AM  
Jun-19-21 05:12AM  
Jun-18-21 06:22AM  
Jun-17-21 08:00AM  
May-20-21 08:00AM  
May-19-21 08:47AM  
May-18-21 09:06AM  
Apr-20-21 08:45AM  
Apr-15-21 08:30AM  
Apr-06-21 08:30AM  
Mar-25-21 07:30AM  
Mar-18-21 08:00AM  
Mar-14-21 08:14AM  
Mar-12-21 07:36AM  
Mar-11-21 04:15PM  
Mar-04-21 08:30AM  
Feb-25-21 08:30AM  
Feb-20-21 03:00AM  
Feb-08-21 08:30AM  
Jan-11-21 08:30AM  
Dec-10-20 08:30AM  
Dec-01-20 08:08AM  
Nov-30-20 04:05PM  
Nov-19-20 06:45AM  
Nov-13-20 07:30AM  
Nov-09-20 08:30AM  
Nov-02-20 04:05PM  
Sep-10-20 08:30AM  
Aug-24-20 10:19AM  
Aug-20-20 08:00AM  
Aug-17-20 08:30AM  
Aug-10-20 08:30AM  
Aug-05-20 08:30AM  
Jul-23-20 08:25AM  
Jul-22-20 04:05PM  
Jul-07-20 08:30AM  
May-21-20 06:30AM  
May-17-20 12:30PM  
May-07-20 08:30AM  
Mar-26-20 06:30AM  
Mar-16-20 04:15PM  
Feb-04-20 07:30AM  
Dec-18-19 04:30PM  
Dec-11-19 05:00PM  
Nov-21-19 07:00AM  
Nov-18-19 08:37AM  
Nov-07-19 04:30PM  
Oct-07-19 08:00AM  
Sep-23-19 08:00AM  
Sep-19-19 11:36AM  
Aug-20-19 07:00AM  
Aug-15-19 07:00AM  
Aug-05-19 08:00AM  
Jul-11-19 12:23PM  
Jul-02-19 07:00AM  
Jul-01-19 08:00AM  
Jun-27-19 07:00AM  
Mar-28-19 07:00AM  
Mar-27-19 11:02AM  
Mar-07-19 07:00AM  
Jan-31-19 08:00AM  
Jan-22-19 08:00AM  
Jan-10-19 07:00AM  
Dec-11-18 09:32AM  
Nov-08-18 08:00AM  
Oct-02-18 08:00AM  
Sep-21-18 09:15AM  
Aug-20-18 04:05PM  
Aug-09-18 12:00PM  
Aug-01-18 08:00AM  
Jul-02-18 04:05PM  
Jun-28-18 08:53AM  
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.